Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Obesity (2005)|October 30, 2013
Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapyS K Malin, A Samat, K Wolski, et al.
Circulation|December 6, 2001
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialM A Lauer, P L Houghtaling, J G Peterson, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 studyG Leibowitz, A Cahn, D L Bhatt, et al.
Journal of Internal Medicine|March 10, 2010
Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery diseaseL Mechtouff, E Touzé, P G Steg, et al.
Diabetes, Obesity & Metabolism|October 8, 2015
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trialL A Leiter, H Teoh, O Mosenzon, et al.
Circulation|January 11, 2000
Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT InvestigatorsS P Marso, D L Bhatt, M T Roe, et al.
European Journal of Neurology|May 29, 2009
High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH RegistryF T Aichner, R Topakian, M J Alberts, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events TrialM Vardi, B L Cryer, M Cohen, et al.
Diabetes/Metabolism Research and Reviews|April 9, 2013
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trialO Mosenzon, I Raz, B M Scirica, et al.
Circulation|July 6, 2000
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesionsF A Cura, D L Bhatt, A M Lincoff, et al.
Pageof 6